Biopharma

What Biopharma does

Biopharma is a Ukrainian biopharmaceutical company founded in 1896 that develops and manufactures immunobiological drugs derived from human donor blood plasma. It is the first Ukrainian manufacturer of plasma-derived medicines and operates as a vertically integrated plasma-processing enterprise, controlling the full chain from its proprietary Biopharma Plasma donor centers through manufacturing at a fractionation facility with 1,000,000 liters of annual throughput capacity. The company collects approximately 200,000 liters of plasma annually from over 100,000 donors across 250,000 donations, with each sample screened for HIV, hepatitis B and C, and syphilis before use. The current 580-person operation is producing at industrial scale; a new fractionation plant in Uzhhorod is at the final construction stage, accompanied by a 5,000 square meter laboratory complex and four additional plasma donor centers, all of which will materially expand production and R&D capacity.

The business model is sales-led and based on direct supply of plasma-derived pharmaceutical products (including the named Bioven brand) to government healthcare systems and medical institutions. Domestically, Biopharma supplies Ukrainian medical institutions across the country; internationally, it exports to over 20 countries spanning Latin America, South and Central Asia, and the Middle East, with active drug registration processes underway in the EU, Turkey, Mexico, Chile, Peru, Argentina, Paraguay, and Hong Kong. Pricing is not publicly disclosed, consistent with negotiated government procurement contracts. The company operates under GMP manufacturing standards and is led by President Kostiantyn Yefymenko, with what appears to be a privately held, founder/management-led ownership structure and no disclosed external investors. The company has cumulatively invested $150 million into its plasma operations, including $18.5 million in the most recent year, signaling a major ongoing capital deployment phase.

Name

Biopharma

Legal name

Biopharma

Website

https://biopharma.ua

Company type

Private

Founded year

1896

Operating status

Operating

Short description

Biopharma is a 129-year-old Ukrainian biopharmaceutical company that vertically integrates plasma collection (100,000+ donors annually) with fractionation manufacturing (1M liter capacity) to produce life-saving blood plasma-derived medicines, supplying Ukrainian government healthcare and exporting to 20+ countries.

Ownership category

akta.pro rank

Product category

Plasma-Derived Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Plasma Fractionation & Purification Manufacturing (HLAIAHAI)

akta.pro secondary industries

Plasma Collection & Donor Services (Plasmapheresis Centers) (HLAIAHAH), Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI), Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH), Plasma-Derived Therapy Quality, Safety & Pharmacovigilance (Pathogen Reduction/Testing) (HLAIAHAK)

Keywords

• Plasma fractionation manufacturing
• Blood plasma products
• Immunobiological pharmaceuticals
• Plasma-derived medicines
• Pharmaceutical manufacturing

Headquarters

HQ city

Kyiv

HQ country

Ukraine

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Infrastructure

Revenue model

1. Blood Plasma Products: Manufacturing and sale of life-saving pharmaceutical products derived from human donor plasma, including immunobiological drugs distributed to medical institutions and exported internationally to 20+ countries.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Biopharma develops and manufactures life-saving pharmaceutical drugs derived from human donor blood plasma through its proprietary plasma fractionation facility. The company operates an integrated supply chain spanning plasma collection at its own Biopharma Plasma donor centers, comprehensive pathogen screening, and GMP-compliant manufacturing of immunobiological pharmaceutical products for distribution to medical institutions.

Product overview

Biopharma is an immunobiological pharmaceutical company operating as a vertically integrated plasma-processing enterprise. The company operates a network of Biopharma Plasma donor centers to collect raw plasma, then processes it at their fractionation facility (capacity: 1,000,000 liters per year) to manufacture life-saving blood plasma-derived medicinal products. Bioven represents a named product brand. With 129 years of history since 1896, the company produces next-generation medicines for domestic use and export to 20+ countries, adhering to GMP manufacturing standards.

Differentiator

Problem solved

Functional benefit

Brands

• Biopharma Plasma: Network of plasma donor centers operated by Biopharma for collecting blood plasma

Products and services

• Blood Plasma-Derived Medicinal Products

Quantifiable outcome

• 1,000,000 liters annual plasma processing capacity - sufficient to meet Ukraine's domestic needs for blood plasma products
• +2 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Ukrainian Healthcare InstitutionscoreOthersBiopharma supplies blood plasma-derived pharmaceutical products to medical institutions throughout Ukraine, ensuring access to life-saving medications for patients nationwide. The company positions itself as critical infrastructure for national healthcare supply.
• Biopharma Plasma DonorscoreOthersOver 100,000 plasma donors contribute to the company's raw material supply annually through Biopharma Plasma donation centers. Donors undergo health screening and blood analysis before plasma collection, enabling sustainable production of blood products.
• Global Teacher Prize UkraineminorGTM or Marketing PartnerBiopharma supported the winner of Global Teacher Prize Ukraine with 500,000 UAH for educational project implementation, demonstrating corporate social responsibility and educational sector engagement.
• Medical/Scientific CommunitycoreStrategic or Co-development PartnerBiopharma collaborates with the broader medical and scientific community through publishing research (Bioven® in ScienceDirect), providing educational events, and supporting professional development for healthcare sector specialists in Ukraine and internationally.

Scale indicators9 records

Recent moves9 records

Expansion highlights4 records

Direct peers

• CSL Behring: CSL Behring is the global leader in plasma fractionation, producing immunoglobulins, albumins, and clotting factors. It directly competes with Biopharma as a vertically integrated plasma-derived therapeutics manufacturer serving similar hospital and government customers worldwide.
• Grifols: Grifols is one of the world's largest plasma fractionators with an integrated donor-center network and broad therapeutic product portfolio. It competes head-to-head with Biopharma in plasma-derived medicines and operates a comparable vertically integrated business model.
• Octapharma: Octapharma is a privately held Swiss global plasma fractionator producing immunoglobulins, coagulation factors, and albumin. It is one of the few large-scale fractionators worldwide at the same technological level as Biopharma and targets overlapping therapeutic and geographic markets.
• Kedrion Biopharma: Kedrion is a privately held Italian plasma fractionator producing plasma-derived therapies for global markets. As a similarly structured privately owned fractionator, it is one of the closest direct comparables to Biopharma in business model and product portfolio.
• Biotest AG: Biotest is a German plasma fractionator specializing in immunoglobulins, coagulation factors, and albumins. It is one of roughly 25 large-scale fractionation facilities worldwide and serves a comparable product portfolio to Biopharma.
• LFB (Laboratoire Français du Fractionnement et des Biotechnologies): LFB is a French state-linked plasma fractionator producing plasma-derived medicinal products for European and international markets. It is directly comparable to Biopharma as a domestically anchored fractionator serving government healthcare systems.

Broad incumbents

• Takeda (Plasma-Derived Therapies): Takeda acquired Shire/Baxalta and operates a large plasma-derived therapies business (immunoglobulin and albumin franchises) as part of its broader rare-disease portfolio. It overlaps with Biopharma's therapeutic focus but at much larger scale and across additional specialty areas.

Regional players

• Sanquin Plasma Products: Sanquin is the Dutch national blood supply organization with a plasma products division that fractionates plasma into therapeutics. While primarily serving the Netherlands, it shares Biopharma's model of integrated donor collection and national fractionation for plasma-derived medicines.

Emerging players

• ADMA Biologics: ADMA Biologics is a US-based plasma fractionator focused on immune globulins for immune-deficient patients. It is an emerging peer with a narrower product line but operates in the same plasma therapeutics category as Biopharma.
• Hualan Biological Engineering: Hualan Biological is one of China's largest plasma fractionators producing immunoglobulins and other blood products. It is comparable to Biopharma in scale and product mix, but operates in a different geography and serves the domestic Chinese market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biopharma-plasma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biopharma